Skip to main content
Download PDF

Targeting the SphK1/S1P/PFKFB3 axis suppresses hepatocellular carcinoma progression by disrupting glycolytic energy supply that drives tumor angiogenesis

Journal of Translational Medicine volume 22, Article number: 43 (2024) Cite this article

Abstract

Background

Hepatocellular carcinoma (HCC) remains a leading life-threatening health challenge worldwide, with pressing needs for novel therapeutic strategies. Sphingosine kinase 1 (SphK1), a well-established pro-cancer enzyme, is aberrantly overexpressed in a multitude of malignancies, including HCC. Our previous research has shown that genetic ablation of Sphk1 mitigates HCC progression in mice. Therefore, the development of PF-543, a highly selective SphK1 inhibitor, opens a new avenue for HCC treatment. However, the anti-cancer efficacy of PF-543 has not yet been investigated in primary cancer models in vivo, thereby limiting its further translation.

Methods

Building upon the identification of the active form of SphK1 as a viable therapeutic target in human HCC specimens, we assessed the capacity of PF-543 in suppressing tumor progression using a diethylnitrosamine-induced mouse model of primary HCC. We further delineated its underlying mechanisms in both HCC and endothelial cells. Key findings were validated in Sphk1 knockout mice and lentiviral-mediated SphK1 knockdown cells.

Results

SphK1 activity was found to be elevated in human HCC tissues. Administration of PF-543 effectively abrogated hepatic SphK1 activity and significantly suppressed HCC progression in diethylnitrosamine-treated mice. The primary mechanism of action was through the inhibition of tumor neovascularization, as PF-543 disrupted endothelial cell angiogenesis even in a pro-angiogenic milieu. Mechanistically, PF-543 induced proteasomal degradation of the critical glycolytic enzyme 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3, thus restricting the energy supply essential for tumor angiogenesis. These effects of PF-543 could be reversed upon S1P supplementation in an S1P receptor-dependent manner.

Conclusions

This study provides the first in vivo evidence supporting the potential of PF-543 as an effective anti-HCC agent. It also uncovers previously undescribed links between the pro-cancer, pro-angiogenic and pro-glycolytic roles of the SphK1/S1P/S1P receptor axis. Importantly, unlike conventional anti-HCC drugs that target individual pro-angiogenic drivers, PF-543 impairs the PFKFB3-dictated glycolytic energy engine that fuels tumor angiogenesis, representing a novel and potentially safer therapeutic strategy for HCC.

Introduction

Hepatocellular carcinoma (HCC) accounts for more than 90% of primary liver cancers, which is the third leading cause of cancer-related deaths worldwide [1]. HCC is one of the most vascularized solid tumors, in which aberrant neovascularization increases the access of tumors to blood and nutrient supplies, promoting cancer cell proliferation, immune cell infiltration, tumor growth and metastasis [2, 3]. Clinically, increased tumor angiogenesis is positively correlated with HCC tumor volume and aggressiveness [4]. Vascular endothelial growth factor A (VEGF-A) and its receptor VEGFR2 represent major tumor angiogenic mechanisms. Over 90% of advanced HCC cases exhibit significantly elevated VEGF-A levels [5]. Currently, therapeutic agents, such as sorafenib and bevacizumab, primarily target VEGF-A/VEGFR2 to impede HCC progression [6, 7]. However, blocking VEGF-A/VEGFR-2 does not adequately abrogate tumor angiogenesis due to the redundancy of other pro-angiogenic growth factors [5, 8]. As such, these agents show limited therapeutic effectiveness [9, 10]. Therefore, new anti-angiogenic strategies should be considered in HCC treatment.

Endothelial cells predominantly utilize glycolysis for energy production [11]. Notably, glycolysis is further increased by ~ 30% in tumor endothelial cells, which supports their sprouting, migration and tube formation during tumor neovascularization [12, 13]. These processes are dictated by the glycolytic activator 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) [11, 12]. Knockout (KO) or inhibition of PFKFB3 inhibits tumor angiogenesis, growth and metastasis, promotes tumor vessel normalization and improves chemotherapy, irrespective of VEGF-A presence [12, 14]. Targeting PFKFB3-mediated glycolytic energy supply for tumor angiogenesis represents a distinct, potentially superior anti-angiogenic strategy, compared to molecularly targeting individual pro-angiogenic drivers [8, 13]. This approach warrants further exploration in HCC therapeutics.

Sphingolipids are a class of essential lipids with extensive roles in cellular structure and signaling. As a rate-limiting enzyme in the catabolism of sphingolipids, sphingosine kinase 1 (SphK1) catalyzes the conversion of ceramide and sphingosine into sphingosine 1-phosphate (S1P) [15, 16]. SphK1 is aberrantly overexpressed in various cancers, including HCC, and correlates with poor prognoses [17,18,19]. SphK1 levels are elevated in a mouse model of HCC induced by diethylnitrosamine (DEN) [20], while germline Sphk1-KO suppresses HCC development in these mice [21]. It is noteworthy that SphK1 and S1P are critical regulators of angiogenesis. SphK1/S1P promotes angiogenesis in endothelial cells and matrigel plugs [22, 23]. In contrast, depletion of S1P impairs vascular development [24] and suppresses tumor growth in xenograft and allograft models by inhibiting VEGF-A-induced neovascularization [23]. Therefore, it is now important to investigate how SphK1/S1P promotes angiogenesis in endothelial cells and whether this regulation can be exploited for HCC treatment.

Given the well-documented pro-cancer role of SphK1, its highly selective inhibitor, PF-543, emerges as a promising candidate for cancer therapy [25]. PF-543 exhibits a notably low inhibition constant Ki of 3.6 nM against SphK1 in vitro [25], and it decreases S1P production in a range of cell types [25,26,27,28]. Intriguingly, PF-543 inhibits hepatocyte growth factor-induced sprouting angiogenesis in human lung microvascular endothelial cells [29]. To date, PF-543 has never been tested in any primary cancer models in vivo. In this study, we assessed the anti-angiogenic and anti-cancer effects of PF-543 in DEN-induced mouse HCC and elucidated its underlying anti-HCC mechanisms. Our study uncovered a previously unidentified pathway that links the SphK1/S1P/S1P receptor axis and PFKFB3-mediated glycolysis in the regulation of angiogenesis. It also demonstrated that pharmacological targeting of SphK1 offers a novel strategy for inhibiting tumor angiogenesis by disrupting glycolytic energy production, with potential significance for the development of effective HCC treatments.

Materials and methods

Human HCC specimens

Human HCC and adjacent para-tumorous tissue specimens were obtained from the Royal Prince Alfred Hospital (RPAH), Sydney, Australia. The sample collection was authorized by the Sydney Local Health District Human Research Ethics Committee (SLHD-HREC, #2019/ETH13790). All subjects provided informed consent prior to specimen acquisition.

Animal work

Wild-type (WT) and Sphk1-KO mice on a C57BL/6J background were used in compliance with protocols (#2019-033 for PF-543 treatment and #2014-007 for Sphk1-KO) approved by the Research Ethics and Governance Office, RPAH. Sphk1-KO mice were obtained from Dr Richard Proia, National Institutes of Health, USA [30]. Mice were housed on a 12-hour light/dark cycle and were allowed food and water ad libitum. Male mice aged 12–14 days were intraperitoneally injected with DEN (Sigma-Aldrich) at 25 mg/kg body weight to induce liver tumors. PF-543 (Selleckchem) was initially dissolved in dimethyl sulfoxide and further diluted in a solvent consisting of 40% PEG-300, 5% Tween 80 and water. At 25 weeks of age, mice were randomly assigned to two groups and intraperitoneally injected with either PF-543 at 25 mg/kg or vehicle every other day for 12 weeks.

Cell culture

Huh7 HCC cell line was obtained from and authenticated by CellBank Australia, human dermal microvascular endothelial cells (HMEC-1) were originally from the American Type Culture Collection, while primary human umbilical vein endothelial cells (HUVECs) were isolated from umbilical cords authorized by the SLHD-HREC (#2019/ETH06859). Cells were maintained in a 5% CO2 incubator using the previously detailed culture media [31,32,33]. Huh7 and HMEC-1 cells were tested mycoplasma-free. Short hairpin RNAs targeting SphK1 (#a or if not specified, 5ʹ-GCAGCTTCCTTGAACCATTAT-3ʹ; #b, 5ʹ-CGCTGTGCCTTAGTGTCTACT-3ʹ) were constructed in pLKO.1 lentiviral vector (Sigma-Aldrich). The lentivirus was generated in HEK293T cells using plasmids obtained from Dr Didier Trono through Addgene, including pMD2.G, pMDLg/pRRE and pRSV-Rev [34]. PF-543 and W146 used for cell culture were purchased from Cayman Chemical; MG-132 was from Calbiochem; VEGF-A was from R&D Systems; while D-erythro S1P was from Enzo Life Sciences.

Lipidomics

Lipids were extracted using a 1:1 mixture of methanol and butanol containing a panel of internal lipid standards (Avanti® Polar Lipids). Sphingolipids were quantified using targeted lipidomics on a TSQ Altis triple quadrupole mass spectrometer, following lipid separation using an Agilent Eclipse Plus C8 column on a Vanquish™ ultra high-performance liquid chromatography system [35]. Peaks were integrated using Xcalibur [35]. Absolute concentrations were determined by normalization against corresponding internal standards and tissue weight. Hierarchical clustering was employed to group similar patterns of lipid changes using Euclidean distance and Ward’s algorithm, where Z-scores were calculated to measure the relative deviation of individual lipid concentrations from the mean values (Metaboanalyst 5.0).

Tissue staining

Liver histology was examined by hematoxylin and eosin (H&E) staining [33]. Immunohistochemistry (IHC) and immunofluorescent (IF) staining were conducted on paraffin-embedded sections and cryosections, respectively, using antibodies against SphK1 (Santa Cruz Biotechnology), phospho-SphK1 (Proteintech), Ki67 (Abcam), CD31 (CST for IHC and BD Pharmingen for IF), cleaved caspase-3 (Cell Signaling Technology, CST) and PFKFB3 (Proteintech). Brightfield Images were captured using Nikon Ni-E Widefield and Zeiss Axio Scan Z1 microscopes, while IF images were obtained on a Nikon C2 confocal microscope. Images were quantified using ImageJ.

Cell viability and cell death

Cell viability was determined by MTS assay (Promega). Luminescence was measured at 490 nm using a TECAN Infinite M1000 Pro plate reader. Cell death was examined following propidium iodide staining on a BD LSRII (BD™ Biosciences) flow cytometer [36]. Data analysis was performed using FlowJo.

Colony formation

Huh7 cells were treated with PF-543 for 10 days. The medium containing PF-543 was refreshed every 3 days. Colonies were fixed using 4% cold paraformaldehyde and stained with 0.5% w/v crystal violet [37]. Images were captured using a ChemiDoc™ Touch Imaging System (Bio-Rad Laboratories) and quantified using ImageJ.

Endothelial cell migration

Cells were seeded in the upper chambers of transwell inserts with 8 μm-pore polycarbonate membrane filter (Sigma-Aldrich). After 12 h of culture, migrated cells in the lower chambers were fixed with 4% paraformaldehyde and stained with 0.5% w/v crystal violet for counting.

Endothelial cell tube formation

Cells were seeded onto polymerized growth factor reduced matrigel (Sigma-Aldrich) in 96-well plates, containing 50 ng/ml VEGF-A or a conditioned medium collected from 72 h culture of Huh7 HCC cells. Images of vessel-like tubular network formation were captured at 6–8 h using a Nikon Ti-E Spinning Disk microscope and analyzed using the Angiogenesis plugin in ImageJ.

Endothelial cell sprouting

HUVEC spheroids were allowed to form in a medium containing 2% methylcellulose (Sigma-Aldrich), before being transferred to plates coated with a mixture of collagen I (Sigma-Aldrich) and methylcellulose [38]. Following the treatment, spheroids were fixed in 4% paraformaldehyde, imaged on a Nikon Ti-E Spinning Disk microscope and quantified using ImageJ.

Pathway commons analysis

To assess the associations between glycolytic and angiogenic (represented by VEGF signaling) pathways, we downloaded 128 relevant genes from the KEGG database, including PFKFB3 and SPHK1. Utilizing the GenRev algorithm, we extracted a subnetwork from the human interactome, sourced from the Pathway Commons database (www.pathwaycommons.org). This database was selected for its comprehensive and reliable interaction data, minimizing noise and bias. The subnetwork reflected the shortest pathway linkages among the selected genes within the interactome.

Western blotting

Proteins were extracted from mouse liver tissues and HUVECs [33]. Immunoblotting was conducted using antibodies against p-VEGFR2, t-VEGFR2, glucose transporter 1 (GLUT1), caspase-3, ubiquitin, GAPDH and β-actin from CST, SphK1 from Santa Cruz Biotechnology, CD31 from Abcam as well as phospho-SphK1, SphK2 and PFKFB3 from Proteintech. Chemiluminescence was detected using a Bio-Rad ChemiDoc™ Touch Imaging System.

Quantitative RT-PCR analysis

RNA was extracted using TRIZol (Thermo Fisher), and reverse transcription was performed using a High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher), as previously described [39]. PCR was conducted on a Roche Lightcycler 480 machine using SensiFAST™ SYBR Lo-ROX Kit (Bioline). Primer sets used for PCR were human PFKFB3 F-CAGTTGTGGCCTCCAATATC, R-GGCTTCATAGCAACTGATCC [40]; human β-ACTIN F-CATGTACGTTGCTATCCAGGC, R- CTCCTTAATGTCACGCACGAT [41].

Seahorse glycolysis assay

Glycolysis was determined using the Seahorse XF Glycolysis Stress Test Kit (Agilent) on an XFe96 analyzer. After the treatment, cells were seeded in collagen-precoated 96-well microplates. Extracellular acidification rates were measured by serial injections of glucose, oligomycin and 2-deoxy-D-glucose.

Statistics

Comparisons between two groups were analyzed by unpaired two-tailed t-tests, and multiple comparisons were analyzed by one-way ANOVA with Tukey tests, using GraphPad Prism (version 9.5). Differences at values of p < 0.05 were considered significant.

Results

PF-543 inhibits SphK1 activity in DEN-treated mice

Consistent with previous findings [21], SphK1 expression was increased in human HCC relative to adjacent non-tumorous tissues (Fig. 1A). To further elucidate the functional implications of the increased SphK1 activity in human HCC, we quantified the expression of its phosphorylated, active form - phospho-SphK1-S225 [42]. We observed a 7-fold upregulation of phospho-SphK1-S225 in human HCC tissues (Fig. 1A). To assess the therapeutic potential of SphK1 inhibition, we induced HCC-like liver cancer in mice with a single injection of DEN. Mice were then treated with PF-543 or vehicle on alternate days for 12 weeks, commencing at 25 weeks of age when initial neoplastic lesions were established (Fig. 1B). Body weights remained comparable between the two groups throughout the study (Fig. 1C). Notably, PF-543 significantly reduced liver mass by 25.2% (Fig. 1D). To ascertain the in vivo inhibitory effects of PF-543 on SphK1 activity, we examined the levels of phospho-SphK1 and its enzymatic product S1P, 24 h post-final PF-543 injection. PF-543 decreased SphK1 phosphorylation and total protein expression by 80% and 40%, respectively, in the liver, without affecting SphK2 (Fig. 1E). In addition, we assessed sphingolipidomic alterations following PF-543 treatment in the liver. Among 69 identified sphingolipid species, PF-543 specifically reduced hepatic S1P levels by 54.9% (p < 0.001) (Additional file 1: Fig. S1 and Fig. 1F). In line with these observations, PF-543 also markedly decreased plasma S1P levels by 50% (Additional file 1: Fig. S2). These findings indicate that effective SphK1 inhibition was sustained across the dosing intervals. In contrast, PF-543 had minimal impact on ceramide and sphingosine levels (Fig. 1F and Additional file 1:  Figs. S1, S2).

Fig. 1
figure 1

PF-543 inhibits SphK1 activity in DEN-treated mice. A Total and phospho-SphK1 levels were examined using immunohistochemical staining in tumorous (T) and para-tumorous (para-T) tissues of human HCC specimens; scale bar = 50 μm; n = 10. B Schematic illustration of treatment schedules for in vivo studies, created with BioRender.com. C Body weight over 12 weeks of vehicle (veh) or PF-543 (PF) treatment. D Liver mass was weighed. E phospho(p)-SphK1 SphK1 and SphK2 protein levels in liver tissues were determined using Western blotting. F Hepatic levels of ceramide (Cer), sphingosine (Sph), and S1P were analyzed using lipidomics. C-F n = 9. Data are expressed as mean ± SD. *p < 0.05; ***p < 0.001

Full size image

Inhibition of SphK1 suppresses HCC progression in DEN-treated mice

Subsequently, we assessed the anti-HCC efficacy of PF-543 in DEN-treated mice. Remarkably, PF-543 treatment led to a 51% reduction in the number of macroscopically visible tumors and a 67% decrease in maximal tumor size (Fig. 2A). PF-543 also significantly decreased intrahepatic tumor number and size by 47% and 58%, respectively (Fig. 2B). In line with these findings, immunohistochemical analysis revealed a 3-fold reduction in the proportion of cells positive for the proliferation marker Ki67 in liver tumors from PF-543-treated mice, as compared to vehicle controls (Fig. 2C). To further understand the anti-HCC mechanisms of PF-543, we examined its anti-cancer properties in Huh7 HCC cells. Consistent with in vivo data, PF-543 markedly reduced S1P levels by 68% in Huh7 cells (Additional file 1: Fig. S3A). Intriguingly, despite its evident anti-proliferative effects in vivo, PF-543 did not affect HCC cell viability in vitro (Additional file 1:  Fig. S3B). In addition, PF-543 neither induced cell death nor suppressed clonogenicity (Additional file 1:  Fig. S3C and S3D). Furthermore, PF-543 did not induce caspase-3 cleavage in liver tissues, indicating that apoptosis was not activated (Additional file 1: Fig. S4). Collectively, these data suggest that the anti-HCC actions of PF-543 observed in vivo were not mediated through direct cytotoxicity on HCC cells.

Fig. 2
figure 2

Inhibition of SphK1 suppresses HCC progression in DEN-treated mice. DEN-injected mice were treated with vehicle (veh) or PF-543 (PF) for 12 weeks. A The number and maximal diameter of visible liver tumors were quantified from macroscopic images. B The number and maximal diameter of intrahepatic liver tumors were quantified from the scanning of the entire H&E-stained liver tissue sections. C Cell proliferation in non-tumorous (NT) and tumorous (T) liver tissues was stained and quantified using Ki67 immunohistochemistry; scale bar = 50 μm. Data are expressed as mean ± SD. n = 9. *p < 0.05; **p < 0.01; ***p < 0.001

Full size image

SphK1 inhibition or ablation reduces vessel density in HCC

Given the critical role of tumor neovascularization in HCC progression and the pro-angiogenic effects of SphK1, we examined the impacts of PF-543 on intratumoral vessel density in DEN-induced HCC. The vessel density in liver tumors, as indicated by CD31 positive area, was 8.2 times greater than that in the adjacent non-tumorous tissues in the vehicle-treated group, demonstrating marked tumor neovascularization (Fig. 3A). Meanwhile, PF-543 treatment resulted in a 57% reduction in this elevated vessel density (Fig. 3A). To determine whether this anti-angiogenic effects of PF-543 could be attributed specifically to SphK1 inhibition, we conducted a parallel study using Sphk1-KO mice. Genetic ablation of Sphk1 led to a 52% reduction in intratumoral vessel density (Fig. 3B), an effect comparable to that observed with PF-543 treatment. Importantly, PF-543 did not directly alter CD31 expression in endothelial cells (Additional file 1:  Fig. S5). These findings indicate a pivotal role of SphK1 in promoting HCC tumor neovascularization and suggest that targeting SphK1 represents a viable strategy for anti-HCC therapy through the modulation of angiogenesis.

Fig. 3
figure 3

SphK1 inhibition or ablation reduces vessel density in HCC tumors. A DEN-injected mice were treated with vehicle (veh) or PF-543 (PF) for 12 weeks. Blood vessels in non-tumorous (NT) and tumorous (T) liver tissues were stained and quantified by CD31 immunohistochemistry; scale bar = 50 μm; n = 9. B Blood vessels in DEN-injected wild-type (WT) and Sphk1 knockout (KO) mice were examined by CD31 immunohistochemistry; scale bar = 50 μm; n = 5. Data are expressed as mean ± SD. **p < 0.01; ***p < 0.001

Full size image

Inhibition of SphK1 impairs angiogenesis in endothelial cells

To further delineate the anti-angiogenic actions of PF-543, we examined its impacts on various angiogenic parameters in both HUVEC and HMEC-1 endothelial cells. Upon stimulation with VEGF-A, PF-543 significantly decreased key metrics of endothelial tube formation, including the number of junctions, segment lengths and branching lengths, in a concentration-related fashion in both endothelial cell types (Fig. 4A and Additional file 1:  Fig. S6A). In addition, PF-543 also mitigated tube formation in HUVECs exposed to conditioned medium derived from Huh7 HCC cells (Fig. 4B), thereby suggesting a link between its anti-angiogenic and anti-HCC actions observed in vivo. In support, PF-543 markedly inhibited sprouting in HUVEC spheroids, leading to a 78% and 48% reduction in cumulative sprout length and the number of sprouts, respectively (Fig. 4C). Furthermore, the compound significantly attenuated the migratory capabilities of both HUVEC and HMEC-1 cells (Fig. 4D and Additional file 1:  Fig. S6B). Notably, PF-543 did not affect cell proliferation or induce cell death (Fig. 4E, F and Additional file 1:  Fig. S6C, D). Together, these findings implicate SphK1 as a key regulator of angiogenic processes in endothelial cells.

Fig. 4
figure 4

Inhibition of SphK1 impairs angiogenesis in HUVECs. Primary HUVECs were treated with PF-543 at the indicated concentrations for 16 h. A and B Tube formation was induced by 50 ng/ml VEGF-A (A) or conditioned medium collected from Huh7 HCC cell culture (B). Quantification of tube formation is presented as the number of junctions, segment length, and total branching length. kpx, 1000 pixels; scale bar = 200 μm (A) or 100 μm (B); n = 3. C Sprouting assays were performed in three-dimensional spheroids. Quantitation of the sprouting is presented as cumulative sprout length and number of sprouts per spheroid; scale bar = 100 μm; n = 10. D Cell migration was determined by transwell assay, and migrated cells were stained with crystal violet; scale bar = 100 μm; n = 3. E Cell viability was determined using MTS assay; n = 4. F Cell death was assessed using flow cytometry with propidium iodide (PI) staining; PI-, living cells (green); PI+, dead cells (red); n = 3. Data are expressed as mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001

Full size image

SphK1 promotes angiogenesis by regulating PFKFB3

Pathway commons analysis revealed a complex subnetwork comprising 1347 interactions among 128 genes relating to VEGF signaling and glycolysis pathways, including SPHK1 (Additional file 1:  Fig. S7). This intricate web of connections suggested a potential role for SphK1 in the regulation of angiogenesis via glycolysis. To address this, we evaluated the impacts of PF-543 on key angiogenic and glycolytic regulators in HUVECs. Notably, PF-543 selectively downregulated the expression of PFKFB3, without affecting the levels of phospho-VEGFR2, total VEGFR2 or GLUT1, (Fig. 5A). This was also observed in DEN-treated mice, where elevated PFKFB3 levels in tumor endothelial cells and adjacent tumorous tissues were dramatically attenuated by PF-543 administration (Additional file 1:  Fig. S8). Interestingly, PFKFB3 mRNA levels were paradoxically increased in HUVECs following PF-543 treatment (Additional file 1:  Fig. S9), thereby ruling out transcriptional regulation. Instead, the PF-543-mediated reduction in PFKFB3 protein expression was abrogated by pre-treatment of cells with the proteasomal inhibitor MG-132, suggesting that PF-543 promoted the proteasomal degradation of PFKFB3 (Fig. 5B). In line with the pivotal role of PFKFB3 in glycolytic regulation, PF-543 treatment significantly decreased both glycolytic rate and capacity in VEGF-A-stimulated HUVECs (Fig. 5C). A similar glycolytic inhibition was observed upon SphK1 knockdown (Fig. 5D). Taken together, these findings unveil a hitherto unidentified functional interplay between SphK1 and PFKFB3 in the regulation of endothelial cell glycolysis, which PF-543 can modulate.

Fig. 5
figure 5

SphK1 promotes angiogenesis by regulating the glycolytic modulator PFKFB3. A Primary HUVECs were treated with 5 µM PF-543 for 16 h, prior to stimulation with 50 ng/ml VEGF-A for 15 min. B Following 1 h pre-treatment with 10 µM MG-132, primary HUVECs were treated with PF-543 at 5 µM for 16 h. A and B Western blotting analyses of the indicated proteins; n = 3. C and D Glycolytic rate, capacity and reserve were determined using Seahorse real-time glycolytic stress assay in PF-543-treated (C) or shRNA-mediated SphK1 knockdown (D) primary HUVECs. ECAR, extracellular acidification rate; n = 5. Data are expressed as mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001

Full size image

SphK1 promotes glycolysis and angiogenesis through S1P in a receptor-dependent manner

We also identified a 6.1-fold increase in PFKFB3 expression in human HCC relative to paratumorous tissues (Additional file 1:  Fig. S10A). Interestingly, PFKFB3 expression was significantly correlated with that of phospho-SphK1, but not total SphK1, among individuals (Additional file 1:  Fig. S10B). This suggests that S1P production by SphK1 is critical in the regulation of PFKFB3 expression and its associated functions. To elucidate this, we supplemented PF-543-treated HUVECs with exogenous S1P. PF-543 alone led to an 80.5% reduction in intracellular S1P levels, which was reversed upon S1P supplementation (Fig. 6A). In contrast, S1P treatment did not alter cellular levels of other sphingolipids, such as sphingosine and ceramide (Fig. 6A). Under these conditions, S1P supplementation effectively reversed PFKFB3 expression, without altering the levels of phosphorylated or total SphK1 (Fig. 6B). Importantly, the addition of S1P restored glycolytic rate and capacity and also normalized tube formation and cell migration, despite the ongoing SphK1 inhibition by PF-543 (Fig. 6C–E). Finally, we examined whether S1P-mediated functional restoration was receptor-dependent. S1P1 is the predominant S1P receptor isoform implicated in angiogenesis [43]. Blocking S1P1 with its specific antagonist W146 abrogated the S1P-mediated restoration of PFKFB3 levels, glycolysis, tube formation and cell migration in PF-543-treated HUVECs (Fig. 6B–E). Collectively, these findings strongly indicate that SphK1-derived S1P, rather than SphK1 itself, played a critical role in modulating PFKFB3-mediated glycolytic energy supply for angiogenesis, and this regulation was S1P1-dependent.

Fig. 6
figure 6

S1P is required for glycolysis and angiogenesis in an S1P1-dependent manner. Primary HUVECs were treated with 5 µM PF-543 (PF) and 0.5 µM S1P (S) for 16 h, with 2 µM S1P1 antagonist W146 added 1 h prior to these treatments. A Levels of ceramide (Cer), sphingosine (Sph) and S1P were analyzed using lipidomics; n = 4. B phospho(p)-SphK1, SphK1 and PFKFB3 protein levels were determined using Western blotting; n = 3. C Glycolytic rate, capacity and reserve were examined using Seahorse real-time glycolytic stress assay. ECAR, extracellular acidification rate; n = 6. D Tube formation was quantified as the number of junctions, segment length, and total branching length. kpx, 1000 pixels; scale bar = 200 μm; n = 4. E Cell migration was determined by transwell assay, and migrated cells were stained with crystal violet; scale bar = 100 μm; n = 3. Data are expressed as mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001

Full size image

Discussion

The therapeutic potential of PF-543 has previously been demonstrated in xenograft models of several cancer types, including colorectal cancer, triple-negative breast cancer and large-cell lung carcinoma [44,45,46]. However, its efficacy in primary cancer models remains unexplored. This study showed the anti-cancer effects of PF-543 against DEN-induced primary liver cancer in mice and also elucidated the underlying mechanisms (Fig. 7). We initiated PF-543 treatment during the liver tumor growth phase in mice, commencing at 23 weeks post-DEN injection, to specifically assess its effects on HCC progression rather than on lesion initiation. This approach is closely aligned with current clinical practice for HCC treatment. It is worth noting that a reduction in tumor growth by > 50% in animal models is generally considered to be an indicator of potential clinical eligibility for new therapeutics [47]. In our study, PF-543 treatment effectively reduced visible and intrahepatic tumor size by 67% and 58%, respectively (Fig. 2), meeting this criterion. In line with this, our previous research has shown that Sphk1-KO results in a comparable 60% reduction in tumor size during the tumor growth phase following DEN administration [21]. These findings, taken together, indicate a critical role of SphK1 in HCC progression and affirm the therapeutic promise of targeted SphK1 inhibition.

Fig. 7
figure 7

Model depicting the anti-HCC actions of PF-543. Elevated pro-angiogenic factors, exemplified by VEGF-A, act through their receptors to drive sprouting angiogenesis in tumor endothelial cells (EC), promoting tumor neovascularization and HCC progression. PFKFB3 serves as a molecular switch in this process, dictating the glycolytic energy supply that is essential for sprouting angiogenesis. The selective SphK1 inhibitor PF-543 abrogates S1P production, subsequently turning off the PFKFB3-mediated glycolytic switch, which leads to the inhibition of sprouting angiogenesis and eventually suppression of HCC progression. The graphical abstract was created with BioRender.com. . The 3D conformer of PF-543 was adapted from PubChem, pubchem.ncbi.nlm.nih.gov, CID 66,577,038

Full size image

Increased secretion of VEGF-A by malignant hepatocytes drives tumor angiogenesis and thus contributes to HCC progression and poor prognosis [4, 5, 48]. Consequently, anti-VEGF-A agents, such as sorafenib and bevacizumab, are clinically used to treat HCC [6, 7]. However, both exhibit significant serious adverse events in approximately one-third of recipients [10]. Our study demonstrated PF-543 as a promising alternative. PF-543 impaired angiogenesis in endothelial cells, even in the presence of VEGF-A or conditioned medium from HCC cells (Fig. 4 and Additional file 1: Fig. S6). These in vitro findings were mirrored in vivo, where PF-543 profoundly reduced intratumoral vessel density in a pro-angiogenic environment (Fig. 3). Importantly, PF-543 achieved this without altering vessel density in non-tumorous liver tissues (Fig. 3) or compromising endothelial cell viability (Fig. 4 and Additional file 1: Fig. S6). Furthermore, PF-543 exhibited potent anti-HCC effects, but with minimal cytotoxicity in both normal and HCC liver cells (Fig. 2 and Additional file 1: Figs. S3, S4). These findings collectively suggest that PF-543 could offer a more targeted and potentially safer anti-angiogenic strategy for HCC treatment.

In healthy adults, endothelial cells remain quiescent. However, upon exposure to elevated levels of pro-angiogenic growth factors, as commonly seen in HCC tumors, endothelial cells are rapidly activated, leading to sprouting angiogenesis [49]. This process demands additional energy and relies on PFKFB3-mediated glycolysis [11, 12]. Previous studies have established that knockdown or inhibition of PFKFB3 suppresses both sprouting angiogenesis and HCC tumor growth, downstream of pro-angiogenic factors [11, 12, 14]. In the present study, PFKFB3 expression was markedly increased in endothelial cells of mouse HCC (Additional file 1: Fig. S8), which is consistent with recent findings in human HCC [14]. The PFKFB3 protein has a relatively short half-life of less than 4 h. Its stability is modulated by multiple post-translational mechanisms, including ubiquitination mediated by anaphase-promoting complex/cyclosome and SKP1/CUL-1/F-box [50, 51], deubiquitination by ubiquitin-specific protease 19, ubiquitin-specific protease 33 and OTU deubiquitinase 4 [52,53,54], methylation by protein arginine methyltransferases 1 and 4) [55], demethylation by lysine demethylase 2 A [56] and phosphorylation (e.g. murine lymphomas 2) [57]. These modifications collectively influence PFKFB3 protein’s stability and its degradation via the proteasomal pathway [50,51,52,53,54,55,56,57]. In the present study, PF-543 treatment significantly decreased PFKFB3 protein levels, which was reversed by the proteasomal inhibitor MG-132 (Fig. 5), indicating that PF-543 induced proteasomal degradation of PFKFB3 protein. Similarly, the PF-543-induced downregulation of PFKFB3 protein was restored by S1P supplementation (Fig. 6), suggesting a critical role for S1P in the regulation of PF-543-induced PFKFB3 protein degradation. Importantly, alterations in S1P levels, PFKFB3 protein expression and endothelial cell glycolysis were closely linked (Fig. 6), unveiling novel mechanistic and functional connections between S1P and PFKFB3. In contrast to its effects on PFKFB3 protein and functional glycolysis, PF-543 increased PFKFB3 mRNA levels (Additional file 1: Fig. S9). In addition, when proteasomal degradation was inhibited, PF-543 treatment strongly increased PFKFB3 protein expression (Fig. 5). This observation was in line with the noted increase in PFKFB3 mRNA levels, suggesting a transcriptional activation. It is well-documented that the regulation of PFKFB3 mRNA is even more complex. Transcriptional activation of the PFKFB3 gene is dictated by a broad range of transcription factors, such as specificity protein 1, activating protein 2, progesterone receptor, nuclear factor 1, estrogen receptor, hypoxia-inducible factor 1α, nuclear factor-κB and yes-associated protein 1, that target an extensive 3500 bp region upstream from the transcription start site [58,59,60]. In view of this regulatory complexity, future studies could be undertaken to address the specific mechanisms by which S1P regulates PFKFB3 mRNA and protein in greater detail.

We previously proposed three modes of action for SphK: the S1P receptor-dependent mode, the intracellular partner mode and the substrate depletion mode [15]. In the present study, exogenous S1P supplementation in HUVECs reversed the PF-543-induced inhibition of glycolysis and angiogenesis, when ceramide and sphingosine levels remained unchanged (Fig. 6). This indicates that PF-543 primarily acted via S1P depletion rather than ceramide or sphingosine accumulation, thus ruling out substrate depletion as the mode of action. Interestingly, the addition of S1P failed to recover SphK1 phospho-activation or expression (Fig. 6), which negates the possibility that PF-543 exerted its effects through intracellular partners of SphK1. To further dissect whether PF-543 functioned through an S1P receptor-dependent mode, we co-treated cells with the selective S1P1 antagonist W146. Of the five S1P receptor isoforms, S1P1 is predominantly involved in vascular development and function [43]. Both global and endothelial cell-specific ablation of S1P1 leads to defective vascular development in mouse embryos [61, 62]. Here, we revealed that W146 significantly abrogated the S1P-mediated restoration of glycolysis and angiogenesis in PF-543-treated HUVECs (Fig. 6). This is the first evidence that implicates an S1P receptor, specifically S1P1, in the regulation of PFKFB3 expression and glycolysis in endothelial cells. In line, S1P increases glycolysis in osteosarcoma cells via S1P3, the predominant S1P receptor isoform in these cancer cells [63]. Our findings reinforce the notion that S1P modulates sprouting angiogenesis via an “inside-out” signaling mechanism [64]. However, the precise mechanism by which S1P/S1P1 modulates PFKFB3 in endothelial cells remains to be elucidated. A deeper understanding of this regulation could potentially enhance the management of various neovascular conditions, not limited to HCC [13].

In summary, the present study provides both experimental and mechanistic evidence demonstrating the therapeutic potential of the selective SphK1 inhibitor PF-543 in HCC. The anti-HCC effects of PF-543 were primarily attributed to the suppression of tumor angiogenesis rather than direct cytotoxicity on HCC cells. Mechanistically, PF-543 treatment reduced S1P production in endothelial cells, which impaired the PFKFB3-mediated glycolytic energy supply for tumor angiogenesis. This represents a significant paradigm that is distinct from the current growth factor-centric anti-angiogenic strategy in HCC treatment. These newly identified anti-HCC actions of PF-543, along with its apparent safety profile, support further preclinical and clinical evaluations in HCC.

Availability of data and materials

All data and materials supporting the conclusion of this study are available from the corresponding author upon reasonable request.

References

  1. Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77:1598.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Zhu AX, Duda DG, Sahani DV, Jain RK. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol. 2011;8:292–301.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Qin S, Li A, Yi M, Yu S, Zhang M, Wu K. Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. J Hematol Oncol. 2019;12:27.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Calderaro J, Ziol M, Paradis V, Zucman-Rossi J. Molecular and histological correlations in liver cancer. J Hepatol. 2019;71:616–30.

    Article  CAS  PubMed  Google Scholar 

  5. Moawad AW, Szklaruk J, Lall C, Blair KJ, Kaseb AO, Kamath A, et al. Angiogenesis in hepatocellular carcinoma; pathophysiology, targeted therapy, and role of imaging. J Hepatocell Carcinoma. 2020;7:77–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6.

    Article  PubMed  Google Scholar 

  7. Llovet JM, Pinyol R, Kelley RK, El-Khoueiry A, Reeves HL, Wang XW, et al. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nat Cancer. 2022;3:386–401.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Falkenberg KD, Rohlenova K, Luo Y, Carmeliet P. The metabolic engine of endothelial cells. Nat Metab. 2019;1:937–46.

    Article  PubMed  Google Scholar 

  9. Su GL, Altayar O, O’Shea R, Shah R, Estfan B, Wenzell C, et al. AGA clinical practice guideline on systemic therapy for hepatocellular carcinoma. Gastroenterology. 2022;162:920–34.

    Article  PubMed  Google Scholar 

  10. Altayar O, Shah R, Chang CY, Falck-Ytter Y, Muir AJ. AGA technical review on systemic therapies for hepatocellular carcinoma. Gastroenterology. 2022;162:937–51.

    Article  PubMed  Google Scholar 

  11. De Bock K, Georgiadou M, Schoors S, Kuchnio A, Wong BW, Cantelmo AR, et al. Role of PFKFB3-driven glycolysis in vessel sprouting. Cell. 2013;154:651–63.

    Article  PubMed  Google Scholar 

  12. Cantelmo AR, Conradi LC, Brajic A, Goveia J, Kalucka J, Pircher A, et al. Inhibition of the glycolytic activator PFKFB3 in endothelium induces tumor vessel normalization, impairs metastasis, and improves chemotherapy. Cancer Cell. 2016;30:968–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Li X, Sun X, Carmeliet P. Hallmarks of endothelial cell metabolism in health and disease. Cell Metab. 2019;30:414–33.

    Article  CAS  PubMed  Google Scholar 

  14. Matsumoto K, Noda T, Kobayashi S, Sakano Y, Yokota Y, Iwagami Y, et al. Inhibition of glycolytic activator PFKFB3 suppresses tumor growth and induces tumor vessel normalization in hepatocellular carcinoma. Cancer Lett. 2021;500:29–40.

    Article  CAS  PubMed  Google Scholar 

  15. Qi Y, Wang W, Song Z, Aji G, Liu XT, Xia P. Role of sphingosine kinase in type 2 diabetes mellitus. Front Endocrinol. 2020;11:627076.

    Article  Google Scholar 

  16. Chung LH, Liu D, Liu XT, Qi Y. Ceramide transfer protein (CERT): an overlooked molecular player in Cancer. Int J Mol Sci. 2021;22:13184.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Satyananda V, Oshi M, Tokumaru Y, Maiti A, Hait N, Matsuyama R, et al. Sphingosine 1-phosphate (S1P) produced by sphingosine kinase 1 (SphK1) and exported via ABCC1 is related to hepatocellular carcinoma (HCC) progression. Am J Cancer Res. 2021;11:4394–407.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Cai H, Xie X, Ji L, Ruan X, Zheng Z. Sphingosine kinase 1: a novel Independent prognosis biomarker in hepatocellular carcinoma. Oncol Lett. 2017;13:2316–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Reynolds GM, Visentin B, Sabbadini R. Immunohistochemical detection of sphingosine-1-phosphate and sphingosine kinase-1 in human tissue samples and cell lines. Methods Mol Biol. 2018;1697:43–56.

    Article  CAS  PubMed  Google Scholar 

  20. Sanchez DI, Gonzalez-Fernandez B, San-Miguel B, de Urbina JO, Crespo I, Gonzalez-Gallego J, et al. Melatonin prevents deregulation of the sphingosine kinase/sphingosine 1-phosphate signaling pathway in a mouse model of diethylnitrosamine-induced hepatocellular carcinoma. J Pineal Res. 2017. https://doi.org/10.1111/jpi.12369.

    Article  PubMed  Google Scholar 

  21. Chen J, Qi Y, Zhao Y, Kaczorowski D, Couttas TA, Coleman PR, et al. Deletion of sphingosine kinase 1 inhibits liver tumorigenesis in diethylnitrosamine-treated mice. Oncotarget. 2018;9:15635–49.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Lee OH, Kim YM, Lee YM, Moon EJ, Lee DJ, Kim JH, et al. Sphingosine 1-phosphate induces angiogenesis: its angiogenic action and signaling mechanism in human umbilical vein endothelial cells. Biochem Biophys Res Commun. 1999;264:743–50.

    Article  CAS  PubMed  Google Scholar 

  23. Visentin B, Vekich JA, Sibbald BJ, Cavalli AL, Moreno KM, Matteo RG, et al. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell. 2006;9:225–38.

    Article  CAS  PubMed  Google Scholar 

  24. Mizugishi K, Yamashita T, Olivera A, Miller GF, Spiegel S, Proia RL. Essential role for sphingosine kinases in neural and vascular development. Mol Cell Biol. 2005;25:11113–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Schnute ME, McReynolds MD, Kasten T, Yates M, Jerome G, Rains JW, et al. Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1. Biochem J. 2012;444:79–88.

    Article  CAS  PubMed  Google Scholar 

  26. Cingolani F, Casasampere M, Sanllehi P, Casas J, Bujons J, Fabrias G. Inhibition of dihydroceramide desaturase activity by the sphingosine kinase inhibitor SKI II. J Lipid Res. 2014;55:1711–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Kim SB, Limbu KR, Oh YS, Kim SL, Park SK, Baek DJ, et al. Novel dimer derivatives of PF-543 as potential Antitumor agents for the treatment of non-small cell lung cancer. Pharmaceutics. 2022;14:2035.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Kim SB, Oh YS, Kim KJ, Cho SW, Park SK, Baek DJ, et al. Synthesis of PP2A-Activating PF-543 derivatives and investigation of their inhibitory effects on pancreatic cancer cells. Molecules. 2022;27:3346.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Fu P, Ebenezer DL, Berdyshev EV, Bronova IA, Shaaya M, Harijith A, et al. Role of sphingosine kinase 1 and S1P transporter Spns2 in HGF-mediated lamellipodia formation in lung endothelium. J Biol Chem. 2016;291:27187–203.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Allende ML, Sasaki T, Kawai H, Olivera A, Mi Y, van Echten-Deckert G, et al. Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720. J Biol Chem. 2004;279:52487–92.

    Article  CAS  PubMed  Google Scholar 

  31. Di Bartolo BA, Cartland SP, Prado-Lourenco L, Griffith TS, Gentile C, Ravindran J, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) promotes angiogenesis and ischemia-induced neovascularization via NADPH oxidase 4 (NOX4) and nitric oxide-dependent mechanisms. J Am Heart Assoc. 2015;4:e002527.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Zhao Y, Ting KK, Li J, Cogger VC, Chen J, Johansson-Percival A, et al. Targeting vascular endothelial-cadherin in tumor-associated blood vessels promotes T-cell-mediated immunotherapy. Cancer Res. 2017;77:4434–47.

    Article  CAS  PubMed  Google Scholar 

  33. Liu XT, Chung LH, Liu D, Chen J, Huang Y, Teo JD, et al. Ablation of sphingosine kinase 2 suppresses fatty liver-associated hepatocellular carcinoma via downregulation of ceramide transfer protein. Oncogenesis. 2022;11:67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, et al. A third-generation lentivirus vector with a conditional packaging system. J Virol. 1998;72:8463–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Aji G, Huang Y, Ng ML, Wang W, Lan T, Li M, et al. Regulation of hepatic insulin signaling and glucose homeostasis by sphingosine kinase 2. Proc Natl Acad Sci USA. 2020;117:24434–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Qi Y, Wang W, Chen J, Dai L, Kaczorowski D, Gao X, et al. Sphingosine kinase 1 protects hepatocytes from lipotoxicity via down-regulation of IRE1alpha protein expression. J Biol Chem. 2015;290:23282–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Trapika I, Liu XT, Chung LH, Lai F, Xie C, Zhao Y, et al. Ceramide regulates anti-tumor mechanisms of erianin in androgen-sensitive and castration-resistant prostate cancers. Front Oncol. 2021;11: 738078.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Korff TAugustin HG. Integration of endothelial cells in multicellular spheroids prevents apoptosis and induces differentiation. J Cell Biol. 1998;143:1341–52.

    Article  Google Scholar 

  39. Qi Y, Kapterian TS, Du X, Ma Q, Fei W, Zhang Y, et al. CDP-diacylglycerol synthases regulate the growth of lipid droplets and adipocyte development. J Lipid Res. 2016;57:767–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Yalcin A, Clem BF, Imbert-Fernandez Y, Ozcan SC, Peker S, O’Neal J, et al. 6-Phosphofructo-2-kinase (PFKFB3) promotes cell cycle progression and suppresses apoptosis via Cdk1-mediated phosphorylation of p27. Cell Death Dis. 2014;5:e1337.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Tran C, Heng B, Teo JD, Humphrey SJ, Qi Y, Couttas TA, et al. Sphingosine 1-phosphate but not fingolimod protects neurons against excitotoxic cell death by inducing neurotrophic gene expression in astrocytes. J Neurochem. 2020;153:173–88.

    Article  CAS  PubMed  Google Scholar 

  42. Pitson SM, Moretti PA, Zebol JR, Lynn HE, Xia P, Vadas MA, et al. Activation of sphingosine kinase 1 by ERK1/2-mediated phosphorylation. EMBO J. 2003;22:5491–500.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Cartier A, Leigh T, Liu CH, Hla T. Endothelial sphingosine 1-phosphate receptors promote vascular normalization and antitumor therapy. Proc Natl Acad Sci USA. 2020;117:3157–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Ju T, Gao D, Fang ZY. Targeting colorectal cancer cells by a novel sphingosine kinase 1 inhibitor PF-543. Biochem Biophys Res Commun. 2016;470:728–34.

    Article  CAS  PubMed  Google Scholar 

  45. Lin Z, Li Y, Han X, Fu Z, Tian Z, Li C. Targeting SPHK1/PBX1 axis induced cell cycle arrest in non-small cell lung cancer. Int J Mol Sci. 2022;23:12741.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Zhang S, Chen X, Wu C, Xu H, Xie X, Feng M, et al. Novel sphingosine kinase 1 inhibitor suppresses growth of solid tumor and inhibits the lung metastasis of triple-negative breast cancer. J Med Chem. 2022;65:7697–716.

    Article  CAS  PubMed  Google Scholar 

  47. Richmond ASu Y. Mouse xenograft models vs GEM models for human cancer therapeutics. Dis Model Mech. 2008;1:78–82.

    Article  Google Scholar 

  48. Ma L, Hernandez MO, Zhao Y, Mehta M, Tran B, Kelly M, et al. Tumor cell biodiversity drives microenvironmental reprogramming in liver cancer. Cancer Cell. 2019;36:418–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. De Bock K, Georgiadou M, Carmeliet P. Role of endothelial cell metabolism in vessel sprouting. Cell Metab. 2013;18:634–47.

    Article  PubMed  Google Scholar 

  50. Herrero-Mendez A, Almeida A, Fernandez E, Maestre C, Moncada S, Bolanos JP. The bioenergetic and antioxidant status of neurons is controlled by continuous degradation of a key glycolytic enzyme by APC/C-Cdh1. Nat Cell Biol. 2009;11:747–52.

    Article  CAS  PubMed  Google Scholar 

  51. Tudzarova S, Colombo SL, Stoeber K, Carcamo S, Williams GH, Moncada S. Two ubiquitin ligases, APC/C-Cdh1 and SKP1-CUL1-F (SCF)-beta-TrCP, sequentially regulate glycolysis during the cell cycle. Proc Natl Acad Sci USA. 2011;108:5278–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Boscaro C, Carotti M, Albiero M, Trenti A, Fadini GP, Trevisi L, et al. Non-genomic mechanisms in the estrogen regulation of glycolytic protein levels in endothelial cells. FASEB J. 2020;34:12768–84.

    Article  CAS  PubMed  Google Scholar 

  53. Zhou B, Wang N, Chen Q, Ren J, Fu X, Cheng X. Deubiquitinase USP33 promotes the glycolysis and growth of osteosarcoma by modifying PFKFB3 ubiquitination and degradation. Am J Cancer Res. 2023;13:922–35.

    CAS  PubMed  PubMed Central  Google Scholar 

  54. Wang F, Yin X, Fan YM, Zhang X, Ma C, Jia K, et al. Upregulation of glycolytic enzyme PFKFB3 by deubiquitinase OTUD4 promotes cardiac fibrosis post myocardial infarction. J Mol Med. 2023;101:743–56.

    Article  CAS  PubMed  Google Scholar 

  55. Yamamoto T, Takano N, Ishiwata K, Ohmura M, Nagahata Y, Matsuura T, et al. Reduced methylation of PFKFB3 in cancer cells shunts glucose towards the pentose phosphate pathway. Nat Commun. 2014;5:3480.

    Article  PubMed  Google Scholar 

  56. Liu X, Li J, Wang Z, Meng J, Wang A, Zhao X, et al. KDM2A targets PFKFB3 for ubiquitylation to inhibit the proliferation and angiogenesis of multiple myeloma cells. Front Oncol. 2021;11: 653788.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Lu C, Qiao P, Sun Y, Ren C, Yu Z. Positive regulation of PFKFB3 by PIM2 promotes glycolysis and paclitaxel resistance in Breast cancer. Clin Transl Med. 2021;11: e400.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Shi L, Pan H, Liu Z, Xie J, Han W. Roles of PFKFB3 in cancer. Signal Transduct Target Ther. 2017;2:17044.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Feng Y, Zou R, Zhang X, Shen M, Chen X, Wang J, et al. YAP promotes ocular neovascularization by modifying PFKFB3-driven endothelial glycolysis. Angiogenesis. 2021;24:489–504.

    Article  CAS  PubMed  Google Scholar 

  60. Jones BC, Pohlmann PR, Clarke R, Sengupta S. Treatment against glucose-dependent cancers through metabolic PFKFB3 targeting of glycolytic flux. Cancer Metastasis Rev. 2022;41:447–58.

    Article  CAS  PubMed  Google Scholar 

  61. Allende ML, Yamashita T, Proia RL. G-protein-coupled receptor S1P1 acts within endothelial cells to regulate vascular maturation. Blood. 2003;102:3665–7.

    Article  CAS  PubMed  Google Scholar 

  62. Liu Y, Wada R, Yamashita T, Mi Y, Deng CX, Hobson JP, et al. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest. 2000;106:951–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Shen Y, Zhao S, Wang S, Pan X, Zhang Y, Xu J, et al. S1P/S1PR3 axis promotes aerobic glycolysis by YAP/c-MYC/PGAM1 axis in osteosarcoma. EBioMedicine. 2019;40:210–23.

    Article  PubMed  Google Scholar 

  64. Takabe K, Paugh SW, Milstien S, Spiegel S. Inside-out signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev. 2008;60:181–95.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Prof. Natasha Harvey (University of South Australia), Prof. Stuart Pitson (University of South Australia) and A/Prof. Mathias Francois (Centenary Institute of Cancer Medicine and Cell Biology) for discussions. We also acknowledge subsidized access to Sydney Mass Spectrometry, Sydney Microscopy & Microanalysis and Sydney Cytometry core facilities at The University of Sydney, Australia.

Funding

This study was supported by National Health and Medical Research Council, Australia (NHMRC) Project Grant GNT1162545 (Y.Q), NHMRC Ideas Grant GNT2002660 (A.S.D and Y.Q), New South Wales Health Cardiovascular Early-Mid Researcher Grant G205977 (Y.Q), and Centenary Institute Future Leader Fellowship (Y.Q).

Author information

Author notes

  1. Xin Tracy Liu and Yu Huang contributed equally to this work.

Authors and Affiliations

  1. Centenary Institute of Cancer Medicine and Cell Biology, The University of Sydney, Sydney, NSW, 2050, Australia

    Xin Tracy Liu, Yu Huang, Da Liu, Yingxin Celia Jiang, Long Hoa Chung, Xingxing Daisy Han, Jinbiao Chen, Paul Coleman, Ka Ka Ting, Mathew Alexander Vadas, Mark Douglas Gorrell, Geoffrey William McCaughan, Jennifer Ruth Gamble & Yanfei Qi

  2. School of Science, Technology and Engineering, University of the Sunshine Coast, Maroochydore DC, QLD, 4558, Australia

    Min Zhao

  3. Key Laboratory of Biotechnology and Bioresources Utilization of Ministry of Education, Dalian Minzu University, Dalian, 116600, Liaoning, China

    Yinan Zhao & Shubiao Zhang

  4. School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, 2006, Australia

    Collin Tran & Anthony Simon Don

  5. Sydney Microscopy and Microanalysis, The University of Sydney, Sydney, NSW, 2006, Australia

    Yingying Su

  6. AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney Local Health District, Sydney, NSW, 2050, Australia

    Claude Vincent Dennis, Ken Liu, Mark Douglas Gorrell & Geoffrey William McCaughan

  7. Sydney Mass Spectrometry, The University of Sydney, Sydney, NSW, 2006, Australia

    Atul Bhatnagar

  8. Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, 2006, Australia

    Michael Murray

  9. Heart Research Institute, Sydney, NSW, 2042, Australia

    Mary Meltem Kavurma

Authors
  1. Xin Tracy Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yu Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Da Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yingxin Celia Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Min Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Long Hoa Chung
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xingxing Daisy Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yinan Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jinbiao Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Paul Coleman
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Ka Ka Ting
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Collin Tran
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Yingying Su
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Claude Vincent Dennis
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Atul Bhatnagar
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Ken Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Anthony Simon Don
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Mathew Alexander Vadas
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Mark Douglas Gorrell
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Shubiao Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Michael Murray
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Mary Meltem Kavurma
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. Geoffrey William McCaughan
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. Jennifer Ruth Gamble
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. Yanfei Qi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

YQ – conceptualization, resources, formal analysis, supervision, funding acquisition, validation, writing—original draft, project administration and writing—review and editing. JRG – conceptualization, resources, supervision, validation, methodology, project administration and writing—review and editing. GWM, MMK, MM, SZ, MDG, MAV and ASD – conceptualization, resources, supervision, methodology and writing—review and editing. XTL, YH, DL, YCJ, MZ, LHC, XDH, JC, PC, KKT and CT – data curation, formal analysis, investigation and methodology. YZ, YS, CVD, AB and KL – resource, formal analysis and methodology.

Corresponding author

Correspondence to Yanfei Qi.

Ethics declarations

Ethics approval and consent to participate

All animal experiments were approved by the Research Ethics and Governance Office, Royal Prince Alfred Hospital, Australia. Human sample collection and analyses were authorized by the Sydney Local Health District Human Research Ethics Committee, Prince Alfred Hospital, Australia. Written informed consent was received according to the guidelines.

Competing interests

The authors declare no potential conflicts of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1.

Supplemental Figure 1. PF-543 specifically reduces hepatic S1P levels in DEN-treated mice. Hierarchical clustering heatmap contains all identified sphingolipid species. The clustering dendrogram was determined based on the Euclidean distances between lipid variables using the Ward clustering method. Color keys indicate standardized lipid concentrations in Z-scores, with red denoting higher and blue denoting lower concentrations. ***, p < 0.001; n = 6. Supplemental Figure 2. PF-543 decreases plasma S1P levels in DEN-treated mice. Plasma levels of ceramide (Cer), sphingosine (Sph), and S1P were analyzed using lipidomics. Data are expressed as mean ± SD; n = 9. ***p < 0.001. Supplemental Figure 3. PF-543 exhibits minimal cytotoxicity in Huh7 HCC cells. A Huh7 cells were treated with 5 μM PF-543 (PF) for 16 h, prior to the measurement of ceramide (Cer), sphingosine (Sph) and S1P levels by lipidomics; n = 4. B Cell viability was determined using MTS assay; n = 6. C Cell death was assessed using flow cytometry with propidium iodide (PI) staining; PI-, living cells (green); PI+, dead cells (red); n = 3. D Colony formation assays were performed over ten days of cell culture. The number and size of colonies were quantified; n=4. Data are expressed as mean ± SD. ***p < 0.001. Supplemental Figure 4. PF-543 does not induce apoptosis in the liver. DEN-treated mice were administered with vehicle (veh) or PF-543 (PF) for 12 weeks. A Apoptosis in non-tumorous (NT) and tumorous (T) liver tissues were detected by cleaved caspase-3 immunohistochemistry; scale bar = 50 μm. B Levels of cleaved caspase-3 in liver tissues were examined by Western blotting. n = 9. Supplemental Figure 5. PF-543 does not alter CD31 expression in endothelial cells. HUVECs and HMEC-1 cells were treated with 5 μM PF-543 (PF) for 16 h. CD31 protein levels were determined by Western blotting. Supplemental Figure 6. PF-543 impairs angiogenesis in HMEC-1 cells. HMEC-1 cells were treated with PF-543 at the indicated concentrations for 16 h. A Tube formation was induced by 50 ng/ml VEGF-A. Quantification of the tube formation is presented as the number of junctions, segment length and total branching length. kpx, 1000 pixels; scale bar = 100 μm; n = 3. B Cell migration was determined by transwell assay, and migrated cells were stained and quantified with crystal violet; n = 3. C Cell viability was determined by MTS assay; n = 4. D Cell death was determined using flow cytometry with propidium iodide (PI) staining; PI-, living cells; PI+, dead cells; n = 3. Data are expressed as mean ± SD. ***p < 0.001. Supplemental Figure 7. Network Visualization of Glycolysis and VEGF Signaling Interactions. Genes associated with glycolysis and VEGF signaling pathways were shortlisted from KEGG datasets. The subnetwork was generated by pathway commons analysis, with dotted lines representing known regulatory relationships, physical interactions, and expression correlations among the genes. Node size is proportional to the degree of connectivity within this subnetwork. Supplemental Figure 8. PF-543 reduces PFKFB3 expression in liver tumors. DEN-injected mice were treated with vehicle (veh) or PF-543 (PF) for 12 weeks. Immunofluorescent staining of CD31 (green) and PFKFB3 (red), with DAPI (blue) counterstaining, was conducted in non-tumorous (NT) and tumorous (T) liver tissues; scale bar = 20 μm. Supplemental Figure 9. PF-543 elevates PFKFB3 mRNA expression in HUVECs. Primary HUVECs were treated with 5 μM PF-543 for 16 h. mRNA levels of PFKFB3 were determined by qRT-PCR, relative to β-actin; n = 3. Data are expressed as mean ± SD. ***p < 0.001. Supplemental Figure 10. Phospho-SphK1 and PFKFB3 levels are correlated in human HCC. A PFKFB3 levels were examined using immunohistochemical staining in tumorous (T) and para-tumorous (para-T) tissues of human HCC specimens; scale bar = 50 μm; n = 10. B Non-parametric Spearman correlations between phospho(p)-SphK1, total SphK1 and PFKFB3 expression were analyzed in tumorous tissues. p < 0.05 is considered significant.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, X.T., Huang, Y., Liu, D. et al. Targeting the SphK1/S1P/PFKFB3 axis suppresses hepatocellular carcinoma progression by disrupting glycolytic energy supply that drives tumor angiogenesis. J Transl Med 22, 43 (2024). https://doi.org/10.1186/s12967-023-04830-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12967-023-04830-z

Keywords

Journal of Translational Medicine

ISSN: 1479-5876

Contact us